Calendar | For Your Patients | PHA Main Site | Contact Us | About Us | Not a registered user? Sign up here.

Author Profile

William Auger, MD ,Professor of Clinical Medicine

University of California, San Diego

Medical Degree

University of Rochester, Rochester, NY


Strong Memorial Hospital, Rochester, NY


Ellis Hospital, Schenectady, NY


UC San Diego, School of Medicine, San Diego, CA

Board Certification

Critical Care Medicine
Internal Medicine
Pulmonary Disease 

Special Clinical Interests:

  1. Chronic Thromboembolic Pulmonary Hypertension
  2. Critical Care Medicine

Investigative Interests:

  1. Natural history of deep venous thrombosis and pulmonary embolism; treatment of acute and chronic pulmonary embolic disease.
  2. Direct visualization and imaging of pulmonary thromboembolism.
  3. Acute, high permeability injury associated with re-perfused lung post PTE surgery

Selected Publications:

  1. Auger WR, Smith RM, Spragg RG. Protease release and antiprotease inactivation in a clinical model of acute high permeability lung injury. Am Rev Respir Dis 1988; 137:146.
  2. Moser KM, Auger WR, Fedullo PF. Chronic, major vessel thromboembolic pulmonary hypertension. Circulation 1990;81:1735-43.
  3. Olman MA, Auger WR, Fedullo PF, Moser KM. Pulmonary vascular steal in chronic thromboembolic pulmonary hypertension. Chest 1990;98:1430-4.
  4. Auger WR, Fedullo PF, Moser KM, Buchbinder M, Peterson KL. Chronic major-vessel thromboembolic pulmonary artery obstruction: Appearance at angiography. Radiology 1992;183:393-8.
  5. Jamieson SW, Auger WR, Fedullo PF, Channick R, Kriett JM, Tarazi RY, Moser KM. Experience and results of 150 pulmonary thromboendarterectomy operations over a 29 month period. J Thorac Cardiovasc Surg 1993;106:116-27.
  6. Channick RN, Williams PJ, Johnson FW, Newhart JW, Kirby D, Auger WR, Fedullo PF, Moser KM. Inhalation of nitric oxide results in more favorable hemodynamic and gas exchange responses than prostacyclin in patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1994;149(4):A746.
  7. Auger WR, Moser KM, Comito RM, Kerr KM, Bernard JL, Spragg RG. Efficacy of intravenous ICI 200,880 in the prevention of adult respiratory distress syndrome (ARDS) in patients undergoing pulmonary thromboendarterectomy. Am J Respir Crit Care Med 1994;149(4):A1032.
  8. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shanghnessy RD, Channick RN, Auger WR, Fedullo PF, Smith CM, Kriett JM, Jamieson SW. Atrial septostomy as a bridge to lung transplantation in-patients with severe pulmonary hypertension. Am J Cardiol 1999; 84:682-686.
  9. Kerr KM, Auger WR, March JJ, Comito RM, Fedullo RL, Smits GJ, Kapelanski DP, Fedullo PF, Channick RN, Jamieson SW, Mooser KM. The use of Cylexin (CY-1503) in prevention of reperfusion lung injury in patients undergoing pulmonary thromboendarterectomy. Am J Resp Crit Care Med 2000; 162:14-20.
  10. Bailey CL, Channick RM, Auger WR, Fedullo PF, Kerr KM, Yung GL, Rubin LJ. “High probability” perfusion lung scans in pulmonary veno-occlusive disease. Am J Resp Crit Care Med 2000; 162:1974-1978.
  11. Thistlethwaite PA, Auger WR, Madoni MM, Pradhan S, Kapelanski DP, Jamieson SW. Pulmonary thromboendarterectomy combined with other cardiac operations: indications, surgical approach and outcome. Ann Thorac Surg 2001; 72:13-18.
  12. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345:1465-1472.
  13. Rothman A, Levy DJ, Sklansky MS, Grossfeld PD, Auger WR, Ajami GH, Behling CA. Balloon angioplasty and stenting of multiple intralobar pulmonary arterial stenosis in adult patients. Catheter Cardiovasc Interv 2003; 58(2):252-260.
  14. Jamieson SW, Kapelanski DP, Sakahibara N, Manecke G, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR. Pulmonary endarterectomy- Experience and lessons learned in 1500 cases. Ann Thoracic Surg In press (2003).


Board Certification:

  • Internal Medicine
  • Pulmonary Medicine

San Diego Magazine's "Top Doc" in Critical Care Medicine


Profile Photo


  • CTEPH: Surgical Versus Medical Patient The identification of patients with chronic thromboembolic pulmonary hypertension (CTEPH) is essential as this is a potentially curable form of pulmonary hypertension. This course will highlight the rationale and recommendation for screening all pulmonary hypertensive patients for CTEPH, and will outline the evaluation algorithm for establishing the diagnosis. Working with an experienced PTE surgery center to ascertain whether or not the chronic thromboembolic disease is operable will be emphasized. For those patients with nonsurgical disease, the treatment options of balloon pulmonary angioplasty and pulmonary hypertension targeted medical therapy will be reviewed.
  • WHO Group 4 PH (CTEPH) WHO Group 4 PH (CTEPH, chronic thromboembolic pulmonary hypertension) is a rare disease characterized by a mean pulmonary artery pressure (mPAP) = 25 mmHg, pulmonary artery occlusion pressure = 15 mmHg, and chronic, organized emboli in the pulmonary artery. In this session, the CTEPH clinical definition, the role of screening in all PH patients, risk factors for developing CTEPH, and treatment options will be discussed.

Journal Articles

  • Chronic Thromboembolic Disease: Underdiagnosis and Nonsurgical Options Chronic thromboembolic disease (CTED) remains an important exclusion in patients presenting with pulmonary hypertension. As illustrated by this case, however, exclusion must be rigorous with or without a suggestive history.
  • Pulmonary Hypertension Roundtable: CTEPH Experiences and Expertise On February 6, 2014, a group of physicians with expertise related to Chronic Thromboembolic Pulmonary Hypertension (CTEPH) met on a conference call to discuss topics related to the disease. The call was hosted by the guest editor of this issue, Richard Channick, MD, the Director of the Pulmonary Hypertension and Thromboendarterectomy Program at Massachusetts General Hospital. Dr. Channick was joined by Victor Tapson, MD, Professor of Medicine in the Division of Pulmonary and Critical Care Medicine at Duke University Medical Center and Director of the Duke Pulmonary Vascular Disease Center; Joanna Pepke-Zaba, PhD, FRCP, Lead Physician and Director, National Pulmonary Vascular Diseases Unit at the Papworth Hospital, University of Cambridge, UK; Vallerie McLaughlin, MD, Professor of Internal Medicine at the University of Michigan; and Bill Auger, MD, Professor of Clinical Medicine and Director of Academic Affairs of the PTE Program at University of California-San Diego.